Skip to content
DataLookout
Menu

NCT07863193

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 28 → 35 locations
  2. Minor Trial sites expanded: 23 → 28 locations
    • Start date pushed from Oct 1, 2026 to Oct 21, 2026
  3. Minor Study sites: 23 to 28
    • Start date changed from estimate of Oct 2026 to Oct 1, 2026
  4. Minor Trial sites expanded: 20 → 23 locations
  5. Minor Trial sites expanded: 4 → 20 locations
  6. Minor Study title expanded, about 1 word
  7. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Proportion of participants achieving EGSS success, defined as a score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from their baseline score
Timeframe: Week 12
Absolute change from baseline in inflammatory lesion count (ILC)
Timeframe: Week 12
Absolute change from baseline in non-inflammatory lesion count (ILC)
Timeframe: Week 12

Arms and interventions

DenifanstatExperimental
PlaceboPlacebo comparator

Drugs: Denifanstat

Other: Placebo

Sites

35 sites in 1 country